RxDoctor Payments Data

Kaitlyn Beisecker Levin, MD

Family Medicine · Charlottesville, VANPI 1356557516

Payments from drug & device makers

$7,078in general payments, 2019–2025

Across 441 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$744
  • AstraZeneca$698
  • Novo Nordisk$587
  • Amgen$247
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$7,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,078 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$67,038
Medicare patients
147
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$33,068
MounjaroTirzepatide30$31,357
FarxigaDapagliflozin Propanediol29$21,042
XareltoRivaroxaban17$17,794
TrulicityDulaglutide14$15,176
QuliptaAtogepant13$14,010
EliquisApixaban15$9,654
JardianceEmpagliflozin14$7,318
SymbicortBudesonide/Formoterol Fumarate12$4,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,404
Gabapentin85$3,004
ValacyclovirValacyclovir Hcl21$2,061
Bupropion XlBupropion Hcl39$1,639
Doxycycline Hyclate11$1,580
Metoprolol Succinate56$1,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$744$46,53344 claims
Novo NordiskOzempic$587$33,06828 claims
AstraZenecaFarxiga, Symbicort$698$25,28141 claims
Johnson & JohnsonXarelto$167$17,79417 claims
AbbVieQulipta, Synthroid$2,065$14,82628 claims
PfizerEliquis$1,036$9,65415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →